NCT04676386View on ClinicalTrials.gov

Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy

TerminatedOBSERVATIONAL
Enrollment

29

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2023

Conditions
NSCLC Stage IVNSCLC, Stage IIIC
Interventions
DIAGNOSTIC_TEST

Primary Immune Response (PIR) test by Biodesix, Inc.

Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.

Trial Locations (2)

60612

Rush University Medical Center, Chicago

94070

Addario Lung Cancer Medical Institute (ALCMI), San Carlos

Sponsors

Collaborators (1)

Biodesix, Inc.
All Listed Sponsors
collaborator

Biodesix, Inc.

INDUSTRY

lead

Addario Lung Cancer Medical Institute

OTHER

NCT04676386 - Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based Therapy With or Without the Addition of Platinum Based Chemotherapy | Biotech Hunter | Biotech Hunter